FKONCO

Fresenius Kabi Oncology Limited has, with reference to the Delisting of the equity shares of the Company from the Exchange, submitted to the Exchange the details of the name, address and contact numbers of the Contact Person at RTA and at the Company for solving Investor queries post Delisting.

Members of the Exchange are hereby informed that the trading in the equity shares of Fresenius Kabi Oncology Limited shall be suspended w.e.f. January 03, 2014 (i.e. w.e.f. closing hours of trading on January 02, 2014 ) on account of voluntary delisting pursuant to the SEBI (Delisting of Equity Shares) Regulations, 2009. The admission to dealings in securities of the said company shall be withdrawn (delisted) w.e.f. January 10, 2014. Further, It may be noted that SEBI has informed the Exchange vide its letter dated December 20, 2013 that they have filed an appeal in this matter in the Hon ble

DSP Merrill Lynch Limited has submitted to the Exchange a copy of public announcement ("Public Announcement") issued by Fresenius Kabi (Singapore) Pte Ltd. ("Acquirer") to the public shareholders of Fresenius Kabi Oncology Limited ("Company") in respect of the proposed acquisition and consequent delisting of the fully paid-up equity shares of the Company from the BSE Limited ( BSE ) and the National Stock Exchange of India Limited ( NSE ) in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 ("Delisting Regulations"). The Acquirer is the p

Fresenius Kabi Oncology Limited has informed the Exchange that on July 22, 2013 Hon'ble Whole Time Member of the Securities and Exchange Board of India ("SEBI") passed an order, allowing the Company to continue with the delisting offer/process subject to certain terms and conditions as mentioned in the said order. Further, as per this order, the Company has been, inter alia, instructed to complete the delisting process within three months from the date of the order.

Fresenius Kabi Oncology Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from July 29, 2013 to August 08, 2013 (both days Inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on August 08, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that the Company has received a letter dated April 16, 2013 ("Letter") from its promoter shareholder, Fresenius Kabi (Singapore) Pte Ltd. ("FKSL") notifying the Company of its intention to make a voluntary delisting offer to the public shareholders of the Company to acquire the entire public shareholding of the Company (i.e. 30,063,255 equity shares of Re. 1 each, representing 19% of the share capital of the Company) and delist the equity shares of the Company from the stock exchanges on which the equity shares of the Company are presen

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at their meeting held on May 30, 2012 decided (1) To convene the Annual General Meeting of the Company on August 09, 2012. (2) Fixed the Book Closure period from July 30, 2012 to August 09, 2012 (both days inclusive).

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at their meeting held on May 26, 2011 decided (1) To convene the Annual General Meeting of the Company on August 11, 2011. (2) Fixed the Book Closure period from August 01, 2011 to August 11, 2011 (both days inclusive).

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at their meeting held on May 28, 2010 decided (1) To convene the Annual General Meeting of the Company on July 29, 2010. (2)Fixed the Book Closure period from July 19, 2010 to July 29, 2010 (both days inclusive).

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 30, 2009 have : 1) Decided to convene the Annual General Meeting of the Company on July 29, 2009. 2) Fixed the Book Closure period from July 15, 2009 to July 29, 2009 (both days inclusive). 3) Not recommended any dividend for the year. 4) Approved the alteration of Articles of Association of the Company. 5) Recommended the re-appointment of Dr. Naresh Trehan, as a Director liable to retire by rotation. 6) Recommended the appointment of Dr. Satish B. Kulkarni, Managi

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2008 have: 1) Decided to convene the Annual General Meeting of the Company on July 21, 2008. 2) Fixed the Book Closure period for the annual closure from July 07, 2008 to July 21, 2008 (both days inclusive). 3) Not recommended any dividend for the year. 4) Recommended the appointment of Mr. Mohit Burman, who was appointed as an additional director on the board of the Company on July 26, 2007, as a director liable to retire by rotation. 5) Recommended the re-appointment of Mr

Morgan Stanley India Company Private Limited has informed the Exchange regarding a Public Announcement ("PA") being issued by them ("Manager to the Offer"), on behalf of Fresenius Kabi (Singapore) Pte Ltd ("FKSL" / the "Acquirer") and Fresenius Kabi Austria GmbH ("FKA"), Fresenius SE ("FSE") and Fresenius Finance B.V. ("FEB") being the Persons Acting in Concert ("PAC") with the Acquirer, in compliance with Regulations 10 and 12 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto (the "SEBI (SAST) Re

Dabur Pharma Limited has informed the Exchange that the Board of Directors at their meeting held on May 17, 2007 have: 1) Decided to convene the Annual General Meeting on July 25, 2007. 2) Fixed the Book Closure period for annual closure from July 16, 2007 to July 25, 2007, both days inclusive. 3) The Directors have not recommended any dividend for the year. 4) Mr. Ajay Vij has been appointed as the Chief Executive Officer of the Company.

Dabur Pharma Limited has informed the Exchange that the BoDs at its meeting held on May 16, 2006 has : (1) Convened the Annual General Meeting of the Company on July 14, 2006 (2) Fixed the Book closure period for the purpose of ascertaining the names of shareholders entitled to divided and annual closure from July 03, 2006 to July 14, 2006, if approved at the ensuing AGM.

Dabur Pharma Limited has informed the Exchange of the outcome of the board meeting held on May 30,2005 as follows:1)Convened the AGM on July 26,2005.2)Fixed the book closure period for the purpose of ascertaining the names of shareholders entitled to dividend and for the purpose of annual closure from July 12,2005 to July 18,2005, both days inclusive.3)Decided that dividend on equity shares shall be paid on or after July 29,2005 if approved at the ensuing AGM.